EP1814512A2 - Formes galeniques perorales pour obtenir un effet de retard apres la prise de medicament lors d'un repas - Google Patents

Formes galeniques perorales pour obtenir un effet de retard apres la prise de medicament lors d'un repas

Info

Publication number
EP1814512A2
EP1814512A2 EP05775898A EP05775898A EP1814512A2 EP 1814512 A2 EP1814512 A2 EP 1814512A2 EP 05775898 A EP05775898 A EP 05775898A EP 05775898 A EP05775898 A EP 05775898A EP 1814512 A2 EP1814512 A2 EP 1814512A2
Authority
EP
European Patent Office
Prior art keywords
active ingredient
gas
sustained
release formulation
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05775898A
Other languages
German (de)
English (en)
Inventor
Werner Weitschies
Henning Blume
Ernst Mutschler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aristocon Verwaltungs-GmbH
Original Assignee
Aristocon Verwaltungs-GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aristocon Verwaltungs-GmbH filed Critical Aristocon Verwaltungs-GmbH
Publication of EP1814512A2 publication Critical patent/EP1814512A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a sustained release formulation for peroral administration together with a meal containing at least one active ingredient and optionally one or more pharmaceutically acceptable excipients and an amount of gas generator which allows a substantially homogeneous mixing of the active ingredient with the stomach contents and thus a continuous flooding of the active ingredient ,
  • delays in the systemic tsunami often occur, which are usually characterized by the fact that, compared to fasting administration, the maximum systemic active substance levels are lowered and the time to onset the maximum drug level is prolonged.
  • sustained-release preparations with or after a meal a prolonged phase until the onset of first measurable systemic drug concentrations is often observed in comparison to fasting.
  • the known effervescent mixtures to be taken perorally when used as intended ie the ingestion after disintegration of the effervescent preparation in a suitable liquid, which is mostly water, lead to a particularly rapid onset of the drug.
  • gas developers as solid-delivery excipients is sometimes also suggested as a disintegrants for the preparation of peroral oral tablets or chewable tablets, described, for example, in Oral tablet disintegrant of nimodipine for treating dementia, Faming Zhuanli Shenqing Gongkai Shuomingshu, 6 pp.
  • CODES CNXXEV; Chinese; CN1394605, where gas evolution does not occur until it is taken in the mouth or in the stomach, but the amounts of gas generators incorporated in such dosage forms are too low to prevent the discontinuation of the corresponding active ingredient.
  • DE 691 25 619 T2 relates to controlled release structures achieved by coating an elongated extruded core with a water-insoluble material.
  • Calcium carbonate is mentioned as a possible additive and is unrelated to the controlled release, on the contrary, the presence of calcium carbonate causes just no retardation but a faster release, as shown in the figures of this document. It is the object of the present invention to find dosage forms which avoid the problem of the occurrence of undesirable plasma peak levels as well as delays in the onset of peroral drug administration with or after the meal.
  • the dosage forms are furthermore intended to bring about as uniform as possible a concentration course of the drug in the systemic circulation.
  • gas developers as adjuvants in solid peroral administration forms undesirably low plasma peak levels and delays in the influx in the peroral administration of drugs with or after the meal occur significantly reduced. This is probably due to the fact that due to the amounts of gas developer contained in the dosage forms according to the invention, a preferably homogeneous mixing of the active ingredients also contained or the active ingredient-containing components of the dosage form with the stomach contents occurs.
  • the active ingredient contained in the dosage form can also be completely or partially present in slowly releasing form of the active ingredient.
  • Gastro-resistant forms are also conceivable, in which case the drug can be protected from the stomach environment.
  • sustained-release formulations and / or enteric coatings depending on the active substance, or the like.
  • Conceivable here are, for example, coated or constructed from an excipient matrix particles, such as granules or pellets, or microparticles.
  • an excipient matrix particles such as granules or pellets, or microparticles.
  • Suitable gas developers are substances that release carbon dioxide. Preference is given to sodium bicarbonate, sodium carbonate, calcium carbonate and
  • Magnesium carbonate or mixtures thereof In this case, it is conceivable to mix two or more of the mentioned gas images in any desired ratios.
  • the person skilled in the art will select a suitable composition of gas developer, depending on the active ingredient or combination of active ingredients. As stated above, other substances that release carbon dioxide may also be considered here.
  • such an amount of gas developer is used per single dose, which is a substantially homogeneous
  • this may be at least 50 mg of a gas developer per single dose.
  • these are at least 100 to 150 mg of gas developer per ingestion, more preferably at least 250 mg, more preferably 300 mg, if appropriate administered 500 mg and also up to 1000 mg of gas developer per ingestion.
  • the person skilled in the art will, depending on the active substance and the present galenics, select the required amount of gas developer and determine it in such a way that the effect according to the invention of homogeneous mixing with the gastric contents is achieved.
  • the acid required for the carbon dioxide release which is preferred according to the invention for the gas developers may originate from the gastric contents or may be contained in the dosage form. All non-physiologically acceptable acids are suitable for admixing, and preferred auxiliaries are acid components such as citric acid, tartaric acid and ascorbic acid or mixtures thereof. Particularly preferred is ascorbic acid.
  • the acid or acids according to preferred embodiments of the invention in amounts of 100 to 300 mg, more preferably from 100 to 200 mg, more preferably in an amount of about 200 mg in the dosage form of the invention. The person skilled in the art will choose an appropriate amount of acid, depending on the dosage form.
  • the dosage forms according to the invention are particularly suitable for the following systemically acting drugs: tricyclic antidepressants, such as amitryptiline, doxepin, and imipramine; non-steroidal anti-inflammatory drugs, such as in particular indomethacin, diclofenac and ketoprofen; Analgesics such as oxycodone, orphin, tramadol and tilidine; Anti-epileptic drugs such as carbamazepine, oxcarbazepine, valproic acid, phenytoin and gabapentin; Anti-parkinson agents, such as levodopa and enthacapone; Alpha-Receptor Blockers, such as Doxazosin; Beta-blockers such as bisoprolol, atenolol and metoprolol; Spasmolytics, such as oxybutynin; Anti-dementia drugs such as memantine and donepizil; Thyroid hormones, such as levo
  • the dosage forms of the invention are also particularly suitable for administration of the active ingredients acarbose, miglitol, pancreatic enzymes, ezetemibe, statins, such as atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin and orlistat.
  • statins such as atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin and orlistat.
  • statins such as atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin and orlistat.
  • statins such as atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin and orlistat.
  • the active ingredient acarbose is particularly suitable for administration of the active ingredients acarbose.
  • Dosage forms according to the invention may be coated or uncoated tablets, chewable tablets, capsules, coated or uncoated granules, coated or uncoated powders or suspensions.
  • the required dose of active ingredient per administration may be divided into several individually divided forms, for example two or three tablets or capsules.
  • the required amount of gas developer then refers to the total amount of active ingredient dose taken.
  • Tablet consisting of 500 mg of sodium bicarbonate, 100 mg of acarbose, 100 mg of microcrystalline cellulose, 10 mg of magnesium stearate.
  • Sodium bicarbonate, acarbose and microcrystalline cellulose are mixed in a free-fall mixer, magnesium stearate is added and mixed again briefly.
  • the powder is compressed on a tablet press into a tablet.
  • Tablet consisting of 400 mg sodium bicarbonate, 100 mg citric acid, 50 mg acarbose, 100 mg microcrystalline cellulose, 10 mg magnesium stearate.
  • Sodium bicarbonate, citric acid, acarbose and microcrystalline cellulose are mixed in a free-fall mixer, magnesium stearate is added and mixed again briefly.
  • the powder is compressed on a tablet press into a tablet.
  • Sodium bicarbonate and acarbose are mixed in a free-fall mixer, magnesium stearate is added and mixed again briefly.
  • the powder is filled into a hard gelatin capsule.
  • Example 4 Capsule containing 250 mg of sodium bicarbonate, 50 mg of citric acid, 25 mg of acarbose, 5 mg of magnesium stearate. Sodium bicarbonate, citric acid and acarbose are mixed in a free-fall mixer, magnesium stearate is added and mixed again briefly. The powder is filled into a hard gelatin capsule.
  • Example 5
  • omeprazole consisting of 10 mg omeprazole as pellets in enteric-coated form (omeprazole, Stada), 300 mg sodium bicarbonate, 50 mg ascorbic acid, 5 mg magnesium stearate. Sodium bicarbonate and citric acid are mixed in a free-fall mixer, magnesium stearate and the enteric-coated pellets (omeprazole, stada) are added. It is mixed again. The mixture is filled into a hard gelatin capsule.
  • Example 6 Capsule consisting of 10 mg of omeprazole as pellets in enteric-coated form (omeprazole, Stada), 300 mg of sodium bicarbonate, 50 mg of ascorbic acid, 50 mg of microcrystalline cellulose, 5 mg of magnesium stearate. Sodium bicarbonate, citric acid and microcrystalline cellulose are mixed in a free-fall mixer, after addition of magnesium stearate, the powder is compacted and then coarsely crushed into granules. The granules and the enteric pellets (omeprazole, stada) are mixed. The mixture is filled into a hard gelatin capsule.
  • Example 7 50 mg each of acarbose were mixed with 406 mg of ascorbic acid and 194 mg of sodium bicarbonate in a mortar and filled into a size 1 hard gelatin capsule.
  • Blood samples (1.5 ml each) were obtained at the following time points: 5 min before the start of the breakfast, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min , 55 min, 60 min, 1 h 10min, 1 h 20min, 1 h 30min, 1h 40min, 1h 50min, 2h, 2h 15min, 2h 30min, 2h 45min, 3h, 3h 15min, 3h 30min, 3h 45min, 4h , 4h 20min, 4h 40min, 5h, 5h 20min, 5h 40min, 6h, 6h 20min, 6h 40min, 7h, 7h 20min, 7h 40min, 8h after the start of the breakfast.
  • the blood samples were analyzed for glucose content.
  • FIG. 1 For the glucose blood levels, the result shown in FIG. 1 was obtained.
  • the figure shows that by using the preparation according to the invention, which was applied in this case as a hard gelatin capsule, a significantly flatter and thus advantageous course of the plasma glucose level is achieved. It clearly comes to a long-lasting and uniform effect of acarbose and unwanted "peak concentrations" of the drug can be avoided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une formulation de retard destinée à l'administration perorale lors d'un repas. Cette formulation contient au moins un principe actif et, au choix, une ou plusieurs substances auxiliaires pharmaceutiquement acceptables, ainsi qu'une quantité d'agent générateur de gaz qui permet un mélange largement homogène du principe actif avec le contenu de l'estomac et, donc, un flux d'arrivée continu du principe actif.
EP05775898A 2004-08-31 2005-08-30 Formes galeniques perorales pour obtenir un effet de retard apres la prise de medicament lors d'un repas Withdrawn EP1814512A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004042139A DE102004042139B4 (de) 2004-08-31 2004-08-31 Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
PCT/EP2005/054260 WO2006024638A2 (fr) 2004-08-31 2005-08-30 Formes galeniques perorales pour obtenir un effet de retard apres la prise de medicament lors d'un repas

Publications (1)

Publication Number Publication Date
EP1814512A2 true EP1814512A2 (fr) 2007-08-08

Family

ID=35745691

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05775898A Withdrawn EP1814512A2 (fr) 2004-08-31 2005-08-30 Formes galeniques perorales pour obtenir un effet de retard apres la prise de medicament lors d'un repas

Country Status (7)

Country Link
US (1) US20090010906A1 (fr)
EP (1) EP1814512A2 (fr)
JP (1) JP2008511585A (fr)
DE (1) DE102004042139B4 (fr)
EA (1) EA013429B1 (fr)
UA (1) UA94031C2 (fr)
WO (1) WO2006024638A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007041588A1 (de) * 2007-09-01 2009-03-05 Lts Lohmann Therapie-Systeme Ag Arzneimittel mit Hefe
CN103142552A (zh) * 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235718A2 (fr) * 1986-02-24 1987-09-09 Eisai Co., Ltd. Granule retenu dans l'estomac
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
WO1994010994A1 (fr) * 1992-11-16 1994-05-26 The Boots Company Plc Compositions effervescentes de sel d'ibuprofene
EP0976395A1 (fr) * 1998-07-30 2000-02-02 Lipha Comprimé à libération prolongée d'un médicament dans l'estomac
WO2000015198A1 (fr) * 1998-09-14 2000-03-23 Ranbaxy Laboratories Limited Systeme d'apport medicamenteux regule administre oralement pour une regulation spatiale et temporelle
WO2001010405A1 (fr) * 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Systeme de delivrance orale de medicament a equilibre hydrodynamique
US20010046473A1 (en) * 1997-04-18 2001-11-29 Jerome Besse Gastric-retained pharmaceutical composition and method for its use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1139991A (en) * 1965-07-19 1969-01-15 Armour Pharma Stabilized enzyme composition
GB1573487A (en) * 1977-05-23 1980-08-28 Bristol Myers Co Bile acid binding composition
CA1182049A (fr) * 1981-07-13 1985-02-05 Francis J. Sterbenz Compose d'apap et d'antiacide
EP0205336B1 (fr) * 1985-06-11 1991-09-11 Teijin Limited Préparation pharmaceutique orale à effet entretenn
JPS61286322A (ja) * 1985-06-12 1986-12-16 Teijin Ltd 経口徐放性製剤
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
JPS62207209A (ja) * 1986-03-07 1987-09-11 Teijin Ltd 経口徐放性製剤
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US5004651A (en) * 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US4975281A (en) * 1989-01-30 1990-12-04 E. R. Squibb & Sons, Inc. Anti-ulcer composition
CA2030449A1 (fr) * 1989-11-22 1991-05-23 Eric H. Kuhrts Formule pour comprimes medicamenteux a liberation progressive
US5683719A (en) * 1990-11-22 1997-11-04 British Technology Group Limited Controlled release compositions
GB9025372D0 (en) * 1990-11-22 1991-01-09 Nat Res Dev Pharmaceutical dosage forms
CZ286723B6 (cs) * 1991-01-30 2000-06-14 The Wellcome Foundation Limited Tablety dispergovatelné ve vodě
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
GB0114069D0 (en) * 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
KR20040018394A (ko) * 2001-07-04 2004-03-03 썬 파마슈티컬 인더스트리스 리미티드 위 정체 제어되는 약물 전달 계
AU2002302890A1 (en) * 2002-02-04 2003-12-02 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235718A2 (fr) * 1986-02-24 1987-09-09 Eisai Co., Ltd. Granule retenu dans l'estomac
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
WO1994010994A1 (fr) * 1992-11-16 1994-05-26 The Boots Company Plc Compositions effervescentes de sel d'ibuprofene
US20010046473A1 (en) * 1997-04-18 2001-11-29 Jerome Besse Gastric-retained pharmaceutical composition and method for its use
EP0976395A1 (fr) * 1998-07-30 2000-02-02 Lipha Comprimé à libération prolongée d'un médicament dans l'estomac
WO2000015198A1 (fr) * 1998-09-14 2000-03-23 Ranbaxy Laboratories Limited Systeme d'apport medicamenteux regule administre oralement pour une regulation spatiale et temporelle
WO2001010405A1 (fr) * 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Systeme de delivrance orale de medicament a equilibre hydrodynamique

Also Published As

Publication number Publication date
US20090010906A1 (en) 2009-01-08
DE102004042139A1 (de) 2006-03-02
UA94031C2 (ru) 2011-04-11
EA013429B1 (ru) 2010-04-30
DE102004042139B4 (de) 2009-06-10
WO2006024638A2 (fr) 2006-03-09
EA200700524A1 (ru) 2007-08-31
WO2006024638A3 (fr) 2007-04-05
JP2008511585A (ja) 2008-04-17

Similar Documents

Publication Publication Date Title
EP0068191B2 (fr) Formes orales du dipyridamole
EP0069259B1 (fr) Forme retard de bromhexine et procédé de préparation
DE69922964T2 (de) Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe
DE60221691T2 (de) Tamsulosin tabletten ohne nahrungsmitteleffekt
DE60319252T2 (de) Formulierung von acetaminophen und tramadol mit verzögerter freisetzung
DE69629797T2 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
WO2000078289A1 (fr) Comprime a couches multiples pour l'administration d'une combinaison fixe de tramadol et de diclofenac
EP1020185A2 (fr) Opioides analgésiques à libération contrôlée
DE3822095A1 (de) Neue arzneimittelformulierung sowie verfahren zu deren herstellung
KR20080033354A (ko) 카르비도파 및 레보도파를 함유하는 고형의 연장 방출약학적 조성물
DE602006000819T2 (de) Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
NZ542303A (en) A process for preparing sustained release tablets
DE69530759T2 (de) Filmbeschichtete tablette, die paracetamol und domperidone enthält
EP1185253A2 (fr) Forme galenique orale servant a administrer une combinaison fixe de tramadol et de diclofenac
DE19859636A1 (de) Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
DE202005020881U1 (de) Psychostimulans enthaltende pharmazeutische Zusammensetzung
DE3834794A1 (de) Oral zu verabreichendes mittel zur behandlung von psoriasis
DE10209979A1 (de) Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
WO2006024638A2 (fr) Formes galeniques perorales pour obtenir un effet de retard apres la prise de medicament lors d'un repas
DE102004045037A1 (de) Pharmazeutische Darreichungsformen mit erschwerter Extrahierbarkeit eines Sympathomimetikums aus der Darreichungsform
WO2016091805A2 (fr) Monopréparation de naloxone et comprimé multicouche
EP0667151A1 (fr) Médicament à usage orale contenant le dictofenac sodium
WO2009135623A1 (fr) Médicament à la galanthamine avec libération contrôlée
DE102005048293A1 (de) Retardformulierung für Pralnacasan
JP2008511585A5 (fr)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070326

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17Q First examination report despatched

Effective date: 20090407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130710